A team from Roswell Park Comprehensive Cancer Center has detailed striking findings on the effectiveness of a previously untried combination of old and new drugs as treatment for recurrent ovarian cancer. Emese Zsiros, MD, PhD, FACOG, Director of Research in the Department of Gynecologic Oncology at Roswell Park, shares her team's findings that onequarter of patients who received the combination of pembrolizumab , bevacizumab and a pill form of cyclophosphamide experienced longterm disease control along with excellent quality of life — far outpacing the effectiveness of either existing approved therapies or newer immunotherapies alone.